

Electronic Acknowledgement Receipt

EFS ID:	7718203
Application Number:	09993647
International Application Number:	
Confirmation Number:	1010
Title of Invention:	omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
First Named Inventor/Applicant Name:	Bernd Riedl
Customer Number:	23599
Filer:	Csaba Henter/Caitlin Sickler
Filer Authorized By:	Csaba Henter
Attorney Docket Number:	BAYER 18A
Receipt Date:	01-JUN-2010
Filing Date:	27-NOV-2001
Time Stamp:	13:41:39
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	no
------------------------	----

File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	P47-CHOW- Measurement of MAP kinase activation.pdf	190254 fd9dc5ac656e3eb8345964474554df54c272f0f9	no	7

Warnings:

Information:

2	NPL Documents	P47a-Christensen-et-al-MI-Cancer-Ther-v4-n6-p938.pdf	2078285	no	10
			8fe3ac6353fe6055f662f58b647550db1cf6d332		
Warnings:					
Information:					
3	NPL Documents	P47b-ChuetaCardiototoxicityAssociate dwithTyrosineKinase.PDF	824576	no	9
			0b14444245e15fdf2e1284003b68a4e0409deadb		
Warnings:					
Information:					
4	NPL Documents	P48-CHUSTECKAETAL-BortezomibSorafenibThyroidCancer.pdf	121562	no	2
			e0c3da562b2eac1b0c9502e26baf8489286f88b6		
Warnings:					
Information:					
5	NPL Documents	P49-ClarkSafetyandPharmacokineticsoftheDualActionRafKinaseand.pdf	1034920	no	9
			c2eaf2ee4a6b212855a63595dc5c705ba2d4a2a1		
Warnings:					
Information:					
6	NPL Documents	P50-COPERETCHRISTOPHEETALASIMPLEANDEFFICIENTMETHODFOR THEPREPARATIONOF.PDF	246666	no	4
			35fca5e45b2ed4f201526da7d439399eb46b8989		
Warnings:					
Information:					
7	NPL Documents	P51-Cortes-TargetingTheMicrotubulesInBreastCancerBeyondTaxanes.pdf	1081233	no	11
			b69de9169fe3fa10ad6cd8d2a22785a3a3525d48		
Warnings:					
Information:					
8	NPL Documents	P52-Craig-Mechanismsofdrugrelease.pdf	741123	no	14
			478ed22f72525497059e99f1497d871477699304		
Warnings:					
Information:					
9	NPL Documents	P53a-CrumplinhibitionofRafkinaseAM L.pdf	129960	no	2
			f7afec875758c734aa4383c5be17b84796164f0b		
Warnings:					
Information:					
10	NPL Documents	P53-CRAS-TreatmentNewbornRats.pdf	492222	no	9
			0193b5ff56a34ca7ec8f94e86cbdc3515fce038		
Warnings:					
Information:					

11	NPL Documents	P54- CunninghametalPhaseITrailHR AS.pdf	529224 e9014e4c3c26a1c444cf6d3bfa7eee326896414e	no	7
Warnings:					
Information:					
12	NPL Documents	P55- DansonImprovingOutcomesin AdvancedMalignantMelanoma. pdf	859338 9cc2dcc7f02852a3f5f9fd111ff4812a165093a	no	11
Warnings:					
Information:					
13	NPL Documents	P56- DASMAHAPATRAETALINVITRO COMBINATIONTREATMENTWIT H.pdf	572714 512143e72fa41cd8062701ed0b32ce5370af8a7	no	11
Warnings:					
Information:					
14	NPL Documents	P57- DaumTheInsandOutofRafKina ses.pdf	923597 b8dd50c7c5aaa180ac3dbf8bc2292fec15b79e90	no	7
Warnings:					
Information:					
15	NPL Documents	P58- DAYANETALERTIARYAMINEOX IDATIONUSING.PDF	272220 3db4be570421b9423994357a8c0da85c337be00f	no	4
Warnings:					
Information:					
16	NPL Documents	P59- DeGrendeleActivityoftheRafKin aseInhibitorBAY43-9006inPatie ntswithAdvancedSolidTumors. pdf	222928 dcaa5b0b3ecc0dd5eea690e754c997c58eed972a	no	3
Warnings:					
Information:					
17	NPL Documents	P59a- DehtlingGrosseOnkologie- Pipeline.pdf	124146 98b96eeec5ddb67e317cbc55f5e77f1523f9d5d8	no	2
Warnings:					
Information:					
18	NPL Documents	P60- DENNYWILLIAMAPRODRUGSTR ATEFIESINCANCERTHERAPY. PDF	1565025 a2ec91172957676af6dcde65d7bff33e046273c0	no	19
Warnings:					
Information:					
19	NPL Documents	P60a- DeVitaetalElevatedPreopertives VEGF.pdf	119665 7c4f005633398386817ef069fec30d68d540ace7	no	9
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.